Efficacy and Safety of Once-Daily Combination Therapy with Didanosine, Lamivudine and Nevirapine in Antiretroviral-Naive HIV-Infected Patients
- 1 July 2005
- journal article
- clinical trial
- Published by SAGE Publications in Antiviral Therapy
- Vol. 10 (5), 605-614
- https://doi.org/10.1177/135965350501000509
Abstract
Simplified antiretroviral regimens are needed to improve patient adherence and quality of life. The purpose of this study was to evaluate the efficacy and safety of a once-daily regimen consisting of didanosine (ddI), lamivudine (3TC) and nevirapine (NVP) for adult antiretroviral-naive patients with HIV-1 infection. This was a prospective, one-arm, multicentre pilot study. Daily drug dosage was 250 or 400 mg didanosine, 300mg lamivudine and 400 mg nevirapine. The primary outcome measure was the percentage of patients with a plasma HIV-RNA level 100 cells/microl than in those with a poorer immunological status at baseline, although the number of patients with CD4 counts <100 was low. Four patients died during the study period. Therapy was discontinued in 18 patients due to virological failure in 11, adverse events in seven, loss to follow-up or withdrawal of consent in four and death in one. Eight out of nine patients with available genotype after virological failure showed resistance mutations to NVP (Y181C and others) and 3TC (M184V/I), and four of them also had ddI resistance (L74V). The lipid profile was favourable, with a decrease in the ratio of total-to-high density lipoprotein cholesterol. A once-daily combination of ddI, 3TC and NVP seems to be an effective, safe and easy-to-take regimen in antiretroviral-naive patients, at least in those who do not have severe immunodepression at baseline.Keywords
This publication has 38 references indexed in Scilit:
- Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004)Enfermedades Infecciosas y Microbiología Clínica, 2004
- Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence TrialClinical Infectious Diseases, 2004
- Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/μl or lessAIDS, 2004
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Modeling the Impact of Modified Directly Observed Antiretroviral Therapy on HIV Suppression and Resistance, Disease Progression, and DeathClinical Infectious Diseases, 2004
- Assessment of Cetirizine, an Antihistamine, to Prevent Cutaneous Reactions to Nevirapine Therapy: Results of the Viramune‐Zyrtec Double‐Blind, Placebo‐Controlled TrialClinical Infectious Diseases, 2004
- Once-Daily Administration of AntiretroviralsClinical Pharmacokinetics, 2003
- Efficacy of Nevirapine-Based HAART in HIV-1-Infected, Treatment-Naive Persons with High and Low Baseline Viral LoadsHIV Research & Clinical Practice, 2001
- Once‐Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Human Immunodeficiency Virus–Infected PatientsThe Journal of Infectious Diseases, 2000
- CD4 Lymphocyte Count as a Predictor of the Duration of Highly Active Antiretroviral Therapy–Induced Suppression of Human ImmunodeficiencyVirus LoadThe Journal of Infectious Diseases, 1999